LATANOPROST AND TIMOLOL OPHTHALMIC SOLUTION

Kraj: Kanada

Język: angielski

Źródło: Health Canada

Składnik aktywny:

LATANOPROST; TIMOLOL (TIMOLOL MALEATE)

Dostępny od:

HIKMA CANADA LIMITED

Kod ATC:

S01ED51

INN (International Nazwa):

TIMOLOL, COMBINATIONS

Dawkowanie:

50MCG; 5MG

Forma farmaceutyczna:

SOLUTION

Skład:

LATANOPROST 50MCG; TIMOLOL (TIMOLOL MALEATE) 5MG

Droga podania:

OPHTHALMIC

Sztuk w opakowaniu:

15G/50G

Typ recepty:

Prescription

Dziedzina terapeutyczna:

BETA-ADRENERGIC AGENTS

Podsumowanie produktu:

Active ingredient group (AIG) number: 0248501001; AHFS:

Status autoryzacji:

APPROVED

Data autoryzacji:

2019-07-11

Charakterystyka produktu

_LATANOPROST AND TIMOLOL OPHTHALMIC SOLUTION 1_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
LATANOPROST AND TIMOLOL OPHTHALMIC SOLUTION
Latanoprost and
molol ophthalmic solu on
Solu on, latanoprost 50 mcg /mL and
molol 5 mg / mL as molol maleate, Ophthalmic
Prostaglandin F
2α
Analogue and Beta-adrenergic Receptor Blocker
Submission Control Number: 280721
Hikma Canada Limited
5995 Avebury Road, Suite 804
Mississauga, Ontario
L5R 3P9
Date of Ini
al Authoriza on:
MAY
25, 2022
Date of Revision:
NOV
28, 2023
_LATANOPROST AND TIMOLOL OPHTHALMIC SOLUTION 2_
RECENT MAJOR LABEL CHANGES
None at the time of most recent authorization
Table of Contents
Secons or subsecons that are not applicable at the
me of authoriza on are not listed.
RECENT MAJOR LABEL CHANGES
................................................................................................................................
2
NONE AT THE TIME OF MOST RECENT AUTHORIZATION
.............................................................................................
2
TABLE OF CONTENTS
...................................................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
...........................................................................................................
4
1.
INDICATIONS
......................................................................................................................................................
4
1.1
P
EDIATRICS
...........................................................................................................................................................
4
1.2
G
ERIATRICS
...........................................................................................................................................................
4
2.
CONTRAINDICATIONS
.........................................................................................................................................
4